catalyst calendar
/
← Catalyst calendar

ZBIO biotech catalysts & pipeline

ZENAS BIOPHARMA INC · Data as of 2026-10-25

Upcoming catalysts

ZB021 — IND submission

2026

Zenas expects to submit an IND and initiate Phase 1 clinical development in 2026.
Source filing

ZB022 — IND submission

2026

Zenas expects to submit an IND and initiate Phase 1 clinical development in 2026.
Source filing

obexelimab — Marketing authorization application

H2 2026

Zenas expects to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in the second half of 2026.
Source filing

ZB021 — Initial data

by year-end

ZB021 (oral IL-17AA/AF inhibitor) dosing ongoing in Phase 1 trial; initial clinical data expected by year-end
Source filing

obexelimab — Topline data

4Q 2026

Phase 2 SunStone trial in Systemic Lupus Erythematosus (SLE) topline results expected in 4Q 2026.
Source filing

obexelimab — PDUFA

May 27

Obexelimab BLA submission for the treatment of IgG4-RD accepted by FDA; PDUFA target action date of May 27, 2027
Source filing

Explore the free biotech catalyst calendar